21,981
Total Claims
$3.0M
Drug Cost
1,295
Beneficiaries
$2,297
Cost/Patient
Peer Comparison vs. 18,720 Cardiology providers
+51%
Cost per patient vs peers
$2,297 vs $1,524 avg
Brand vs Generic
100% generic
Brand: 0 claims · $0
Generic: 18,296 claims · $213K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Tafamidis | 37 | $782K |
| Empagliflozin | 624 | $399K |
| Sacubitril/Valsartan | 521 | $353K |
| Dapagliflozin Propanediol | 566 | $339K |
| Apixaban | 508 | $312K |
| Evolocumab | 190 | $118K |
| Mavacamten | 12 | $98K |
| Empaglifloz/Linaglip/Metformin | 111 | $72K |
| Ticagrelor | 148 | $66K |
| Rivaroxaban | 102 | $53K |
| Candesartan/Hydrochlorothiazid | 384 | $44K |
| Sitagliptin Phos/Metformin Hcl | 85 | $41K |
| Candesartan Cilexetil | 375 | $27K |
| Sitagliptin Phosphate | 45 | $26K |
| Atorvastatin Calcium | 2,436 | $18K |
Prescribing Profile
74
Unique Drugs
$1.5M
Patient Profile
72
Avg Age
51%
Female
2.17
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data